Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip 100
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Brought to you by

BI and ViraTherapeutics collaborate for oncolytic virus platform; BI has option to acquire ViraTherapeutics; option exercised

Sep 2016

Executive Summary

Boehringer Ingelheim Pharmaceuticals Inc. entered into a collaboration with ViraTherapeutics GMBH to develop a next generation oncolytic virus platform based on ViraTherapeutics' lead candidate VSV-GP (Vesicular Stomatitis Virus glycoprotein) currently in preclinical development for solid cancers.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Includes M&A Option
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By